SCHEMBL5419396

SCHEMBL5419396

O=C(CCC(=O)c1ccc2c(c1)CCN(C(=O)C(F)(F)F)CC2)NCCCc1ccc(Cl)cc1

nearest known ligand 0.44

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 15/20 0.44
HRH3 Q9Y5N1 2/20 0.43
ESR1 P03372 2/20 0.40
ESR2 Q92731 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14489930 0.90 HRH3 (0.47) MCHR1HRH3
SCHEMBL5416440 0.88 L3MBTL1 (0.46) HRH3
SCHEMBL5413044 0.85 MCHR1 (0.44) MCHR1ESR1ESR2
SCHEMBL5418245 0.83 HRH3 (0.47) MCHR1HRH3
SCHEMBL5418545 0.82 MCHR1 (0.45) MCHR1ESR1ESR2
SCHEMBL14489931 0.82 MCHR1 (0.52) MCHR1HRH3
Hydrochloric Acid SCHEMBL5422736 0.81 MCHR1 (0.51) MCHR1HRH3
SCHEMBL5420488 0.78 HPGD (0.43) ESR1ESR2
SCHEMBL14489935 0.77 NAMPT (0.48)
SCHEMBL14490002 0.76 MCHR1 (0.45) MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7229986-B2 Melanin-concentrating hormone antagonist TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) 2007-06-12 US disclosed
US-7229986-B2 Melanin-concentrating hormone antagonist TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) 2007-06-12 US disclosed
US-20030158177-A1 Treating or preventing obesity TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-08-21 US disclosed
EP-1283199-A1 MELANIN-CONCENTRATING HORMONE ANTAGONIST Takeda Chemical Industries, Ltd. (JP) 2003-02-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158177-A1 Treating or preventing obesity MCHR1, MC1R, NPY1R MCHR1 1/4885HRH3 196/4885ESR1 1689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.